Priscilla de Albuquerque Ribeiro Gondinho1, Paulo Goberlânio de Barros Silva2,3, Mário Roberto Pontes Lisboa1,4, Bruno Almeida Costa5, Duílio Reis da Rocha Filho6, Markus Andret Cavalcante Gifoni7, Marcos Venicio Alves Lima5, Roberto César Pereira Lima Junior1, Mariana Lima Vale1. 1. Laboratório de Farmacologia da Inflamação e do Câncer, Programa de Pós-Graduação em Farmacologia, Drug Research and Development Center (NPDM), Universidade Federal do Ceará, Fortaleza, Brazil. 2. Laboratório de Biologia Molecular e Genética, Hospital Haroldo Juaçaba, Instituto do Câncer do Ceará, Rua Papi Júnior, 1222-Rodolfo Teófilo, Fortaleza, Ceará (CE), 60430-230, Brazil. paulo_goberlanio@yahoo.com.br. 3. Unichristus, Fortaleza, Ceará, Brazil. paulo_goberlanio@yahoo.com.br. 4. Unichristus, Fortaleza, Ceará, Brazil. 5. Laboratório de Biologia Molecular e Genética, Hospital Haroldo Juaçaba, Instituto do Câncer do Ceará, Rua Papi Júnior, 1222-Rodolfo Teófilo, Fortaleza, Ceará (CE), 60430-230, Brazil. 6. Hospital Universitário Walter Cantídio, Universidade Federal do Ceará, Fortaleza, Brazil. 7. Departamento de Ciruegia, Universidade Federal do Ceará, Fortaleza, Brazil.
Abstract
BACKGROUND: Colorectal carcinoma (CRC) is widely treated by chemotherapy based on an intensely neurotoxic drug: oxaliplatin (OXL). We objective to evaluate prospectively the orofacial neurotoxicity during FLOX (fluorouracil + leucovorin + OXL) chemotherapy. METHODS: So, 46 patients with CRC were prospectively evaluated during FLOX chemotherapy by 3 cycles (C) of 6 weeks (W) each. We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale). Patients were asked the following concerning the severity (scores 0-5) of orofacial symptoms: jaw pain, eyelids drooping, throat discomfort, ear pain, tingling in mouth, difficulty with speech, burning or discomfort of the eyes, loss of any vision, feeling shock/pain down back and problems breathing. We summed the scores (0-50) and evaluated the clinicopathological data. Friedman/Dunn, Chi square and multinomial regression logistic tests were used (SPSS 20.0, p < 0.05). RESULTS: There was a significant increase in sum of orofacial neurotoxicity from baseline to C1.W3, C2.W1 and C3.W5 (p < 0.001) due increase in scores of jaw pain (p < 0.001), eyelids drooping (p = 0.034), throat discomfort (p < 0.001), ear pain (p = 0.034), tingling in mouth (p = 0.015), burning/discomfort of your eyes (p < 0.001), loss of any vision (p < 0.001), feeling shock/pain down back (p < 0.001), problems with breathing (p = 0.045), but not difficulty with speech (p = 0.087). Women (p = 0.021) and young patients (p = 0.027) had significant higher prevalence of orofacial neurotoxicity. CONCLUSIONS: FLOX-related orofacial neurotoxicity begins acutely and remains long term with increased incidence in women and younger patients.
BACKGROUND: Colorectal carcinoma (CRC) is widely treated by chemotherapy based on an intensely neurotoxic drug: oxaliplatin (OXL). We objective to evaluate prospectively the orofacial neurotoxicity during FLOX (fluorouracil + leucovorin + OXL) chemotherapy. METHODS: So, 46 patients with CRC were prospectively evaluated during FLOX chemotherapy by 3 cycles (C) of 6 weeks (W) each. We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale). Patients were asked the following concerning the severity (scores 0-5) of orofacial symptoms: jaw pain, eyelids drooping, throat discomfort, ear pain, tingling in mouth, difficulty with speech, burning or discomfort of the eyes, loss of any vision, feeling shock/pain down back and problems breathing. We summed the scores (0-50) and evaluated the clinicopathological data. Friedman/Dunn, Chi square and multinomial regression logistic tests were used (SPSS 20.0, p < 0.05). RESULTS: There was a significant increase in sum of orofacial neurotoxicity from baseline to C1.W3, C2.W1 and C3.W5 (p < 0.001) due increase in scores of jaw pain (p < 0.001), eyelids drooping (p = 0.034), throat discomfort (p < 0.001), ear pain (p = 0.034), tingling in mouth (p = 0.015), burning/discomfort of your eyes (p < 0.001), loss of any vision (p < 0.001), feeling shock/pain down back (p < 0.001), problems with breathing (p = 0.045), but not difficulty with speech (p = 0.087). Women (p = 0.021) and young patients (p = 0.027) had significant higher prevalence of orofacial neurotoxicity. CONCLUSIONS: FLOX-related orofacial neurotoxicity begins acutely and remains long term with increased incidence in women and younger patients.
Authors: A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Andreas A Argyriou; Panagiotis Polychronopoulos; Gregoris Iconomou; Elisabeth Chroni; Haralabos P Kalofonos Journal: Cancer Treat Rev Date: 2008-02-20 Impact factor: 12.111